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Abstract. Increased expression of integrins and focal adhesion kinase (FAK)
is important for the survival, growth and metastasis of melanoma cells. Based on
this well-established observation in oncology, we propose to use degradation of
integrin and FAK proteins as a potential strategy for melanoma cancer therapy. A
low-temperature radio-frequency atmospheric microplasma jet is used to study
their effects on the adhesion molecules of G361 melanoma cells. Microplasma
treatment is shown to (1) cause significant cell detachment from the bottom of
microtiter plates coated with collagen, (2) induce the death of human melanoma
cells, (3) inhibit the expression of integrin α2, integrin α4 and FAK on the cell
surface and finally (4) change well-stretched actin filaments to a diffuse pattern.
These results suggest that cold atmospheric pressure plasmas can strongly inhibit
the adhesion of melanoma cells by reducing the activities of adhesion proteins
such as integrins and FAK, key biomolecules that are known to be important in
malignant transformation and acquisition of metastatic phenotypes.
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1. Introduction
Low-temperature plasmas generated at reduced gas pressures have been an indispensable
technology for many industrial sectors, including microelectronic fabrication and display
devices [1, 2]. Over the past 20 years, there has been growing interest in developing
their counterparts at atmospheric pressure, particularly for biomedical applications such as
bacterial inactivation [3, 4], wound healing [5], dental bleaching [6] and treatment of cancer
cells [7, 8]. Among numerous low-temperature atmospheric pressure plasmas, including
dielectric-barrier discharges [9] and radio-frequency (RF)-driven glow discharges [10],
atmospheric pressure plasma jets feature particularly strongly in the aforementioned biomedical
applications [11]–[15]. It has been known that they could be used to induce cell detachment
and apoptosis (programmed cell death) [16, 17]. This is significant, because cell adhesion
to the extracellular matrix (ECM) is important for many biological processes, such as
embryogenesis [18], tumor invasion and metastasis [19]. Loss of cell adhesion may lead to
a specific type of apoptosis known as ‘anoikis’ [20]. Thus, the ability of plasma to give rise
to cell detachment and apoptosis has important implications for cancer treatment as well as
other biomedical applications. It is, however, unknown what cellular processes may be triggered
in plasma-enabled cell detachment. This study attempts to study whether low-temperature
atmospheric plasmas compromise the physical link of cells to the ECM.
For this work, we consider melanoma cells that require adhesion to the ECM for
their survival, growth and metastasis [21]. The physical link between ECM and the actin
cytoskeleton is mainly mediated by cell-surface adhesion receptors. Integrins form one of the
largest receptor groups and constitute a class of transmembrane glycoproteins that functionally
link the cytoskeleton to the extracellular environment [22]. Their interaction with the actin
cytoskeleton leads to integrins being redistributed on the cell surface and clustered onto specific
structures known as focal adhesions, where the ends of the actin filaments are anchored to the
membrane [23]. While stationary adult cells use the integrin–ECM interactions for anchorage,
cancer cells appear to use these interactions for traction to migrate and possibly also as a
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3stimulus to proliferate. It is therefore of great importance that the integrin–ECM interaction
is studied in plasma-facilitated cell detachment and apoptosis. At the tissue level, integrins
also play key roles in regulating tumor growth, metastasis and angiogenesis. During melanoma
development, the increased expression of integrins enables melanoma cells to convert from
a stationary to a migratory and invasive phenotype [24]. The present study of integrin–ECM
interactions in melanoma cells is likely to have direct implications to relevant tumor growth and
metastasis processes.
To study whether and how low-temperature atmospheric plasmas may affect integrins
and cell adhesion, it is important to consider focal adhesion kinase (FAK), a major signaling
mediator whose activation requires both integrin attachment and cell spreading [25, 26].
FAK is a cytoplasmic tyrosine kinase that is responsible for mediating many cellular
processes, including cell survival, migration and invasion. Unregulated increases in cell survival
mechanisms, migration and invasion can enable tumors to metastasize to distant sites within
the body. Therefore, FAK is often overexpressed in numerous cancers, including melanoma,
breast, colon and thyroid cancers [27]–[29], whereas normal tissues express little detectable
FAK. Moreover, inhibition of FAK expression causes apoptosis in several human tumor cell
lines, including melanoma [30].
Inhibiting the expressions of integrins and FAK proteins may therefore be a good strategy
in melanoma treatment. Significantly low-temperature atmospheric pressure microplasmas have
recently been shown to destroy and degrade biomolecules such as proteins [31, 32], and so
we hypothesize that atmospheric pressure microplasmas could also degrade integrins and FAK
proteins in melanoma cells, compromising their interaction with ECM and ultimately leading
to the induction of cell death. If this could be established, it would open the door to a new
plasma-mediated strategy towards cancer therapy. Up to now, there has been no report on
whether plasma treatment deactivates adhesive molecules such as integrin and FAK proteins
and on whether plasma targeting of adhesion molecules could potentially be used in cancer
therapy. This study takes a first step and investigates at a cellular level whether low-temperature
atmospheric microplasmas inhibit the expression of integrins and FAK proteins at the focal
adhesion sites of human melanoma G361 cells.
2. Materials and methods
2.1. Cold atmospheric pressure microplasma jet
A schematic diagram of the experimental setup is shown in figure 1(a). RF energy at 13.56 MHz
was applied, via an impedance-matching network, to a tungsten wire of 0.4 mm diameter and the
tungsten wire was enclosed within a concentric grounded cylinder having an inner diameter of
6 mm. The electrode unit was therefore of coaxial configuration. With an atmospheric pressure
helium flow rate of 0.5–5 slm (standard liters per minute), a stable plasma was struck as shown
in figure 1(b). The plasma diameter was around 1 mm, and its plume length was variable from
less than a millimeter to a few millimeters, depending on the input RF power and the gas flow
rate. The impedance-matching network was found to be critical in maximizing plasma density.
The RF generator was designed to operate at up to 10 W of input power with a sweeping
step of 0.1 W. The gas temperature at the tip of the microplasma jet was measured using
a temperature strip at the position of the sample and confirmed with rotational temperature
measured from the nitrogen monopositive ion N+2 first negative system (B26+u , v = 0→ X26+g ,
v′ = 0, 388–392 nm).
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4Figure 1. (a) Experimental setup for an RF atmospheric pressure helium plasma
needle at 13.56 MHz and (b) a photograph of the generated plasma at 4 W of
input RF power.
2.2. Optical emission spectroscopy
The optical emission spectrum of the atmospheric pressure microplasma was measured with a
spectrophotometer (SpectraPro 300i, ARC, 15 Discovery Way, Acton, MA 01720, USA) from
the light detected with an intensified charge-coupled device (PI-MAX2, Princeton Instruments,
3660 Quakerbridge Road, Trenton, NJ 08619, USA) in shutter mode, with integration performed
over 10 ms and at a gain of 1.0. The grating used was 600 grooves mm−1 when used to identify
reactive plasma species, and 2400 grooves mm−1 when used to measure rotational temperature.
2.3. Cell culture
G361 melanoma cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 25 mM HEPES, 100µg ml−1 penicillin/streptomycin, 4 mM L-glutamine
and 10% fetal bovine serum at 37 ◦C in a 5% CO2 humidified-air incubator.
2.4. Cell viability assay
The viability of cultured cells was estimated by sodium 3′-[1-(phenylaminocarbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay. XTT solution
was made by completely dissolving XTT in hot media at 1 mg ml−1. This was most easily
accomplished by heating a tube containing medium in a 60 ◦C water bath. Menadione (MEN)
was made up fresh each day as a 100 mM solution in dimethyl sulfoxide, and was added to
the XTT solution immediately before use. Twenty microliters of XTT/MEN was added to each
100µl culture. After an additional 4 h of incubation at 37 ◦C, the optical density of the wells was
determined using a multiwell reader (Quant, Bio-Tek, Winooski, USA) at a test wavelength of
450 nm and a reference wavelength of 650 nm. Each plate contained appropriate blank control
wells containing media, XTT and MEN, but no cells.
2.5. Inhibition of adhesion assay
Flat-bottomed wells in microtiter plates were coated overnight at 4 ◦C with 100µl of collagen
type I (50µg ml−1). G361 cells (4× 105) in 100µl of DMEM were plated in triplicate on each
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5coated well and incubated for 24 h at 37 ◦C. After treating the cells with the RF microplasma,
unbound cells were removed by two gentle washes with phosphate buffered saline (PBS).
Attached cells were quantified by the XTT assay, and absorbance was measured at 450 nm.
The numbers of adhering cells were calculated by reference to the standard curve for G361 cell
suspensions (1× 103/well to 4× 105/well).
2.6. Fluorescence staining
After being treated by the RF microplasma, cells were fixed in 4% paraformaldehyde for 10 min.
Cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min. For filamentous actin
(F-actin) staining, cells on coverslips were labeled with FITC-phalloidin at room temperature
for 30 min, and then rinsed in PBS three times for 5 min each time and mounted onto glass
slides with 50% glycerol in PBS. For antibody staining, cells on coverslips were incubated with
anti-integrin α2, anti-integrin α4 and anti-FAK antibodies for 1 h. Cells were washed thoroughly
and then incubated with goat FITC-anti-mouse secondary antibody for 1 h. Cells were washed
thoroughly in PBS three times for 10 min each. Coverslips were mounted onto glass slides
with 50% glycerol in PBS and observed under a fluorescence microscope (Axioskop, Zeiss,
Germany).
2.7. Western blot analysis
Cells treated with the microplasma were washed twice with ice-cold PBS, re-suspended
in 200µl of ice-cold solubilizing buffer [300 mM NaCl, 50 mM Tris-Cl (pH 7.6), 0.5%
TritonX-100, 2 mM PMSF, 2µg ml−1 aprotinin and 2 g ml−1 leupeptin] and incubated at
4 ◦C for 30 min. The lysates were centrifuged at 14 000 revolutions/min for 15 min at 4 ◦C.
Protein concentrations of cell lysates were determined with the Bradford protein assay (Bio-
Rad, Richmond, CA, USA) and 50µg of protein was loaded onto 7.5–15% SDS–PAGE.
The gels were transferred to a nitrocellulose membrane and reacted with anti-FAK antibody.
Immunostaining with antibodies was performed using enhanced chemiluminescence substrate
(Supersignal West Pico) and detected with LAS-3000PLUS (Fuji Photo Film Company,
Kanagawa, Japan).
2.8. Plasma treatment of G361 melanoma cells
The atmospheric pressure microplasma jet shown in figure 1 was applied to treat G361
melanoma cells in a petri dish. Nominal conditions were (1) an input RF power of 4 W,
(2) a helium flow rate of 2 slm and (3) the plasma-housing unit positioned 3 mm from the
surface of the human melanoma G361 cells.
3. Results and discussions
Plasma conditions were monitored using electrical measurement and optical emission
spectroscopic measurement. In general, the electric circuit incorporating the impedance-
matching network was well controlled. This helped to achieve a good reproducibility of the
findings of our cellular experiments. Reflected RF power from the microplasma was found to
be low in most cases and so the input RF power may be regarded as approximately proportional
to the dissipated power in the microplasma. Gas temperature was measured with a temperature
strip, and was in general consistent with rotational temperature measured from the N+2 band
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6Figure 2. Gas flow rate dependence of gas temperature at the sample point at
different input RF powers.
of 388–392 nm. Figure 2 suggests that gas temperature at the sample point was below 30 ◦C
as long as the input RF power was maintained at no more than 6 W. For all cell experiments
reported here, the input RF was fixed at 4 W and the treatment time was nominally at 15 s.
Therefore, cells under microplasma treatment were unlikely to experience a gas temperature
more than 30 ◦C and all their responses were likely to be non-thermal. It is worth mentioning
that RF-driven atmospheric plasmas are often hotter than their low-frequency counterparts [33],
particularly when driven at large RF power. For our experiments, the input RF power was low
and the gas flow rate was sufficiently high, both helpful in cooling down the gas effluent. The
very short plasma treatment time of 15 s was an additional factor to ensure that cells experienced
non-thermal effects of the RF microplasma jet.
Figure 3 shows optical emission spectra at a fixed input RF power of 4 W and with
different gas flow rates. Similar to other studies of atmospheric pressure plasma jets in helium,
the optical emission spectra are dominated by helium species (particularly around 706 nm) as
well as oxygen and nitrogen lines. The latter stemmed from the mixture of helium flow with
ambient air. Of particular interest is the atomic oxygen line at 777 nm, as oxygen atoms have
been shown to play a major, if not dominating, role in inactivation of both bacteria [4, 34]
and biomolecules [31, 32]. The emission spectra of figure 3 are seen to vary markedly with
the gas flow rate, due to helium gas displacing the air, thus changing the composition of the
gas mixture at the tungsten tip [35, 36]. For example, simulation of gas fluid dynamics using a
computational fluid dynamics code CFD-ACE+ [37] indicates that the molar fraction of air at
the needle tip is lower than 1% when the helium velocity is larger than 0.8 m s−1. A linear gas
velocity of 0.8 m s−1 is expected when the electrode unit of figure 1 is flushed with a gas flow rate
of more than 0.5 slm. This suggests that the oxygen admixture in helium flow at the tungsten
tip was likely to be less than 0.2%. However, the oxygen admixture along the length of the
plasma plume may be slightly larger because a much increased radial diffusion of the working
gas after exiting the electrode unit would reduce the effect of gas displacement. As a rough
estimate, the oxygen content in background helium gas may vary between 0.2% and 2% in our
experiments. This is the range within which bactericidal effects of low-temperature atmospheric
plasma jets were found to be most significant against both microorganisms and biomolecules
[4, 31, 32, 34].
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7Figure 3. Optical emission spectroscopy at 4 W of input RF power and different
gas flow rates from 0.7 to 5 l min−1 (lpm).
Cell migration, homing and settlement during tissue formation, repair, tumor invasion and
metastasis are guided by a complex set of adhesive interactions between cells and the ECM
[18, 19]. These interactions are mediated by cell-surface adhesion receptors, of which the
integrins are known to be one of the largest groups. The cytoplasmic tails of integrin α and
β subunits connect the ECM to the actin cytoskeleton and trigger intracellular signaling by
recruiting many structural and adaptor proteins leading to intracellular kinase cascades. In this
study, G361 cells were plated on collagen-coated wells of a microtiter plate and incubated for
24 h. Treatment of G361 cells using the RF atmospheric microplasma was found to significantly
decrease their adhesion to collagen in a time-dependent manner as shown in figure 4(a). Over
the same time course, figure 4(b) suggests that the viability of plasma-treated G361 cells, as
estimated by the XTT assay, also decreases monotonically. However, it is interesting to note that
after 15 s of the microplasma treatment, about 90% G361 cells seem to have lost their adhesion
capability while the viability of the cell population appears to remain at approximately 20%.
This suggests that the absence of attached G361 cells may be a consequence of not only cell
death but also considerable loss of certain cell functions, particularly adhesion to the ECM.
It is known that actin or other components of the cytoskeleton are organized through
distinct steps during cell adhesion. In the early phases, cells attach and begin to spread on the
substrate, organizing actin into peripheral filopodia. After the adhesive process is completed,
cells are stretched by the tensile forces of actin stress fibers to acquire a spindle shape. Stress
fibers are anchored to the membrane at the focal adhesion structure. Figure 4(c) shows that
many untreated G361 cells take a spindle shape and are likely to have achieved strong adhesion
whereas other G361 cells exhibit a more rounded shape, indicating an incomplete adhesive
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8Figure 4. 15 s treatment of RF atmospheric microplasma inhibited (a) the
adhesion and (b) viability of G361 cells. It also changed the cell morphology
from (c) a spindle shape to (d) a more rounded shape.
process. Following microplasma treatment, figure 4(d) shows that many treated G361 cells
change to a more round shape and even the spindle-shaped cells tend to become swollen
with less defined border lines. These suggest a plasma-mediated compromise of cell functions.
In fact, within a few seconds of plasma treatment when there were many viable G361 cells
(see figure 4(b)), we observed that the usual spindle shape of live cells was changed to the more
rounded shape. This indicates that loss of cell adhesion to ECM was already very significant
prior to cell death, and is consistent with our hypothesis that plasma-facilitated cell death may
be related to integrin–ECM interactions.
Plasma-mediated change of human melanoma cells from their normal states could be seen
in the responses of adhesion proteins, particularly those of F-actin, a major cytoskeletal protein
involved in cell motility [38]. To see this clearly, we stained G361 melanoma cells with the
F-actin-specific probe, FITC-phalloidin, after 15 s of microplasma treatment. As shown in
figure 5, fluorescent-labeled F-actin bundles appear at the edge of the spreading cells (untreated)
whereas plasma-treated cells seem to attain a diffusive pattern of F-actin. This diffusive pattern
lacks the distinct direction of spreading of control cells, and may be regarded as an indication
of compromised or degraded functions of F-actin proteins.
To provide further support to the observation of plasma-mediated compromise of cell
morphology and adhesion proteins in figures 4 and 5, we consider possible plasma damage
to integrin proteins. It is known that integrins regulate the anchorage-independent growth
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9Figure 5. Degradation of well-stretched F-actin into a diffuse pattern by 15 s
atmospheric microplasma treatment: (a) before and (b) after plasma treatment.
Arrows indicate F-actin.
and invasive growth of tumors. In particular, they prevent apoptosis of invading cells and
increase tumor growth [38, 39]. Many studies have reported that the expression of integrins
changes frequently during malignant transformation. Furthermore, up-regulation of expression
of integrins is associated with the acquisition of a more metastatic phenotype [40]. It has been
reported that the expression levels of integrins αv, α2, α3 and α4 are increased in primary and
metastatic melanomas [41, 42]. Therefore, the expression level of integrins αv, α2, α3 and α4
provides a direct indication of whether plasma treatment may influence directly malignant
transformation and acquisition of a more metastatic phenotype. To this end, we performed an
immunocytochemistry assay for integrins α2 and α4 after the G361 melanoma cells were treated
with the RF atmospheric microplasma. Figure 6 shows the results of immunofluorescence
microscopy for integrins α2 and α4 using each integrin-specific antibody. The shape of control
cells is expanded with filopodia, with integrins α2 and α4 being located at the periphery.
Treatment with the RF atmospheric microplasma resulted in a distinct change in cell shape
from a spindle type to a more rounded type, with the expression of integrin disappearing on the
cell surface. It should be emphasized that integrins α2 and α4 were stained with antibodies and
the considerable reduction of their fluorescence intensity after microplasma treatment supports
strongly the idea that these integrins are degraded. These results suggest that the RF atmospheric
microplasma is likely to have degraded integrins α2 and α4 and hence inhibited their activity
in our experiments. Since the plasma condition used in this experiment (4 W for 15 s) would
still support some viable G361 cells (see figure 4(b)), it is unlikely that the observed integrin
degradation resulted from blanket plasma damage to the whole cells. Instead, plasma treatment
may have specifically degraded adhesion proteins of melanoma cells to ECM.
Finally we considered FAK proteins, because their up-regulation and uncontrolled
signaling are known to be responsible for the promotion of malignant phenotypic characteristics
and the resistance to chemotherapy. Figure 7 shows the results of immunocytochemistry and
Western blot analysis. While FAK appears in lamellipodial edges as well as in outlining areas
of control cells without plasma treatment, little expression of FAK is evident in the cells treated
with the RF atmospheric microplasma. Similarly, Western blot analysis indicates significant
reduction at the 125 kDa band. These results are direct evidence of our hypothesis that plasma
treatment inhibits the expression of FAK. It should be mentioned that direct FAK targeting
is known to inhibit the malignant phenotype of cancer cells [43]. Together with consistent
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Figure 6. Inhibiting effects of RF atmospheric pressure helium microplasma
(4 W, 15 s) on the expressions of integrins α2 and α4 in G361 melanoma cells,
with (a) and (b) control cells (α2 and α4 marked with white and yellow arrows,
respectively), and (c) and (d) plasma-treated cells.
Figure 7. Inhibitory effects of atmospheric pressure helium plasma (4 W,
15 s) on the expression of FAK in G361 melanoma cells as shown
(a) before plasma treatment and (b) after plasma treatment, both illustrated with
immunocytochemistry (yellow arrow marking FAK), and (c) with Western blot
analysis.
results for integrins α2 and α4 in figure 6, it is clear that a short treatment of 15 s with the
RF atmospheric microplasma operated at a low input power of 4 W is capable of inhibiting
the expression of integrins α2 and α4 and FAK. Given the significance of integrins α2 and α4
in malignant transformation and that of α2, α4 and FAK in acquisition of a more metastatic
phenotype, the results in figures 6 and 7 are very encouraging.
The results represented in this study are motivated by the need for a basic understanding
of how cold atmospheric plasmas interact with cancer cells. While it is conceivable that plasma
inactivation of adhesion proteins may be used to control the migration of cancer cells and their
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acquisition of a metastatic phenotype, more studies are needed before an effective practical
implementation may be reached. An important issue here is possible UV damage, particularly
around 260 nm in the UVC band (100–280 nm), that may lead to the formation of pyrimidine
dimers that can cause mutagenesis and cell death during DNA replication [44]. If the results
reported here were accompanied by considerable UVC triggered mutagenesis or due to UVC
triggered cell death, the viability of RF atmospheric microplasma as part of a cancer therapy
would become questionable. According to relevant EU guidelines, the maximum allowed UVC
dose rate is 30µW cm−2 [45]. To investigate this, we measured the emission spectrum of the
RF atmospheric plasma jet for the band of 200–900 nm with its emission intensity absolutely
calibrated for the 350–850 nm band, under the condition of 4 W RF power and 2 slm helium
flow. The strongest emission was found to be the helium line at 706 nm with its emission
intensity well below 1µW cm−2, and its emission intensity in the 250–300 nm range was only a
small fraction of 1µW cm−2. With a smaller helium flow rate, emission from the N2 (C-B) band
became proportionally stronger (see figure 3(c)) but the absolute emission intensity remained
well below 1µW cm−2. This is not dissimilar to the emission of similar RF atmospheric helium
plasma jets [46], and suggests that the UVC emission intensity is likely to be well below the
maximum allowed dose rate of 30µW cm−2. Hence UVC irradiation of the RF atmospheric
plasma jet is unlikely to cause mutagenesis and the cell death shown in figure 4 is likely to
be due to plasma treatment rather than UV. It is useful to remark that UVC damage is better
characterized in terms of dose than dose rate and that the maximum allowed dose rate above is
arrived at in a general context of sunburn [45]. The timescale of the sunburn is much greater
than the timescale of atmospheric plasma treatment considered here. Therefore, UVC radiation
associated to the RF atmospheric plasma jet considered is most likely to be below the relevant
safety threshold and the deactivation effects of adhesion proteins shown in figures 4–6 are
triggered by reactive plasma species, particularly reactive oxygen species.
4. Conclusion
An RF atmospheric microplasma jet was used for the treatment of human melanoma cells.
By controlling the input RF power and the flow rate of the background helium gas, the gas
temperature was found to be below 30 ◦C and the plasma effects were predominantly non-
thermal. Optical emission spectra indicated the presence of abundant oxygen species, including
oxygen atoms, which are known to inactivate both microorganisms and proteins.
Short treatment of 15 s with the RF atmospheric microplasma operated at 4 W of input
power was found to change the morphology of G361 melanoma cells from their usual spindle
shape to a more rounded shape when there were still many viable cells. A similar shape change
also occurred for one adhesion protein (filamentous actin). Furthermore, the same plasma
treatment was shown to inhibit the expressions of integrin α2, integrin α4 and FAK, which are
known to be important in malignant transformation and acquisition of metastatic phenotypes.
Finally, microplasma treatment was found to cause a marked reduction in actin filaments and to
induce a diffusive pattern in G361 melanoma cells that lacks directionality of the usual spindle
form. These results indicate that low-temperature atmospheric microplasma could strongly
inhibit the proliferation of melanoma cells through potentially specific degradation to focal
adhesion molecules (e.g. a plasma-mediated molecular process) and hence a new route towards
melanoma cancer therapy. Much needs to be studied further both at a cellular level and at a
tissue level, some of which will be reported in future correspondences.
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